$17.48
▼ -0.7% Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Overview
52-week range
$12
$29
32% of range
Avg surprise (last 2)
-325.0%
Avg reaction (last 1)
+2.3%
100% positive
Latest IV / EM
98%
EM ±4.1% · $17 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.28 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $-0.24 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.76 | $-0.10 | -660.0% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.09 | $-0.10 | +10.0% | — | +2.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.08 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.03 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.02 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.43 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | $-58M |
| Net income | $-216M | $-189M | — | $-232M | $-566M | $-63M | — | $-56M |
| EPS (diluted) | $-0.28 | $-0.24 | — | $-0.31 | $-0.76 | $-0.09 | — | $-0.08 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $419M | $107M | $225M | $239M | $298M | $212M | $105M | $94M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $721M | $617M | $720M | $246M | $309M | $371M | $424M | $490M |
| Total assets | $752M | $648M | $751M | $262M | $324M | $384M | $436M | $503M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $122M | $102M | $92M | $69M | $65M | $39M | $47M | $65M |
| Total equity | $630M | $546M | $659M | $192M | $259M | $344M | $389M | $438M |